Payment overview · 2025
General Payments
$281.78
14 reported records · 6 companies
Healthcare provider profile · identity verified
Stephen Pandolph
Allopathic & Osteopathic Physicians|Family Medicine · STATE COLLEGE, PA · NPI 1053311761
Verified facts
What the public records show
CMS Open Payments records show Stephen Pandolph received $281.78 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.10 | 48.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.21 | 14.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.96 | 11.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.55 | 9.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.83 | 8.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.13 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.78 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.10 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $114.55 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 51 |
| Metformin Hcl | Metformin Hcl | 129 | 35 |
| Spironolactone | Spironolactone | 120 | 29 |
| Valsartan | Valsartan | 109 | 35 |
| Carvedilol | Carvedilol | 101 | 21 |
| Famotidine | Famotidine | 100 | 31 |
| Gabapentin | Gabapentin | 99 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 99 | 38 |
| Allopurinol | Allopurinol | 90 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 27 |
| Prednisone | Prednisone | 86 | 40 |
| Alprazolam | Alprazolam | 84 | 19 |
| Lisinopril | Lisinopril | 83 | 26 |
| Losartan Potassium | Losartan Potassium | 81 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 51 |
| Potassium Chloride | Potassium Chloride | 77 | 22 |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Finasteride | Finasteride | 76 | 23 |
| Eliquis | Apixaban | 68 | 17 |
| Omeprazole | Omeprazole | 67 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 18 |
| Montelukast Sodium | Montelukast Sodium | 63 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 15 |
| Simvastatin | Simvastatin | 62 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 19 |
| Clonazepam | Clonazepam | 55 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 20 |
| Sertraline Hcl | Sertraline Hcl | 53 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Glimepiride | Glimepiride | 47 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 14 |
| Diazepam | Diazepam | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 13 |
| Mupirocin | Mupirocin | 38 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 36 | 11 |
| Mometasone Furoate | Mometasone Furoate | 35 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Azithromycin | Azithromycin | 32 | 24 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Nystatin | Nystatin | 29 | 13 |
| Levofloxacin | Levofloxacin | 27 | 20 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 16 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | suppressed |
| Furosemide | Furosemide | 23 | suppressed |
| Invokana | Canagliflozin | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Quinidine Sulfate | Quinidine Sulfate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nucynta | Tapentadol Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.78 · 14 records | ABBVIE INC. | AREXVY, GEMTESA, NURTEC ODT, QULIPTA, SHINGRIX, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error